Evidence map›Paper›PMID 40796743›Full record

ArticleNature communications2025

A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy.

Katie Maurer, Jackson A Weir, Adi Nagler, Nicholas J Haradhvala, Hariharan Bharadwaj, Jacob Shapiro, Somkene Alakwe, Vipin Kumar, Brianna Waller, Mikaela McDonough and 13 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Katie Maurer *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4160-181X
Jackson A Weir *Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8741-1344
Adi NaglerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nicholas J HaradhvalaBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1113-3135
Hariharan BharadwajDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4550-4811
Jacob ShapiroBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Somkene AlakweBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Vipin KumarBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Brianna WallerDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Mikaela McDonoughDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jamie Dela CruzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Loida LunaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Emma LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Linsey GongBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Qiyu GongBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Mehdi BorjiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Phillip D MichaelsDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Jacob P LaubachDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Geraldine PinkusDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Gad GetzBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0936-0753
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. catherine_wu@dfci.harvard.edu.
Fei ChenBroad Institute of MIT and Harvard, Cambridge, MA, USA. chenf@broadinstitute.org.ORCID http://orcid.org/0000-0003-2308-3649
Caron JacobsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. caron_jacobson@dfci.harvard.edu.

Funding

Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironmentR01CA276865 · NCI · BROAD INSTITUTE, INC. · PI Fei Chen, Catherine Ju-Ying Wu · 2023 to 2026
$2.8M
A platform for multi-modal single nucleus spatial genomics for molecular tumor analysisR33CA291199 · NCI · BROAD INSTITUTE, INC. · PI Fei Chen · 2024 to 2026
$1.2M
NCI NIH HHS R01 CA276865NCI NIH HHS R33 CA291199
6 · The paper itself

Abstract

Reports of secondary malignancies after chimeric antigen receptor (CAR)-T and possible CAR-T derived malignant transformation necessitate caution. Here we describe a patient with diffuse large B-cell lymphoma who developed new lymphadenopathy 2.5 years after CAR-T in the context of COVID-19 infection with histopathologic features consistent with T-cell lymphoma (TCL). Deep molecular interrogation with genomic sequencing and single-cell spatial transcriptomics reveals a highly proliferative clonal T-cell population co-expressing CD4 and CD8 with biallelic TCR rearrangement and no evidence of the CAR construct. The expanded clonotype displayed T follicular helper (TFH) cell transcriptomic programs and occupies immune-excluded spatial niches within the lymph node, supportive of TFH-like neoplastic T cell behavior. Remarkably, the lymphadenopathy spontaneously resolved on interval imaging. Our data underscore the need for better understanding of post-CAR-T clonal T-cell lymphoproliferative disorders to avoid unnecessary treatment and higher specificity in diagnostic methods for TCL.

Indexed as

Immunotherapy, AdoptiveLymph NodesLymphoma, Large B-Cell, DiffuseLymphoma, T-CellT-LymphocytesCOVID-19FemaleHumansLymphadenopathyMaleMiddle AgedReceptors, Chimeric AntigenSARS-CoV-2Receptors, Chimeric Antigen

Identifiers

PMID40796743
PMCPMC12343882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.